Figure 1 (Brixadi 01)
The text describes the labeling of parts of a safety syringe before use, including the plunger head and syringe guard body.*
Brixadi Injection
Product Images NDC 58284-232
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 25 technical images submitted to the FDA as part of the official labeling for Brixadi (NDC 58284-232). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Braeburn Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 2 (Brixadi 02)
This text is a useful description of a safety syringe after use, when the needle protection mechanism is activated. The text describes the appearance of the syringe guard plunger head in this state.*
Figure 3 (Brixadi 03)
This product is a syringe with a syringe guard. Unfortunately, further information is not available.*
Figure 4 (Brixadi 04)
Not available.*
Figure 5 (Brixadi 05)
Figure 6 (Brixadi 06)
Figure 7 (Brixadi 07)
Figure 8 (Brixadi 08)
Figure 9 (Brixadi 09)
Figure 10 (Brixadi 10)
Figure 11 (Brixadi 11)
Figure 12 (Brixadi 12)
Figure 13 (Brixadi 13)
Chemical Structure (Brixadi 14)
Figure 14 (Brixadi 15)
This is a graph that displays the Placebo-Corrected VAS Drug-Liking Score (mm) of BRIXADI injection over time, with respect to Buprenorphine Plasma Concentration (ng/mL). The baseline drug-liking score is compared with the score after BRIXADI injection, with different levels of buprenorphine plasma concentration shown on the X-axis.*
Figure 15 (Brixadi 16)
Figure 16 (Brixadi 17)
Figure 17 (Brixadi 18)
This is a table showing the percentage of participants in a study who received two different treatments: BRIXADI and SLBPNINX (with 213 and 215 participants, respectively). The table also shows the percentages for negative opioid assessments (using urine and self-reported measures) at various time-points (4 weeks, 7 weeks, and 10 weeks). There is no readable information about the value of £0 or what it refers to.*
Carton (Principal Panel)
Description: This appears to be a warning and prescribing information for a medication called "Lynclally". It is administered through injection for subcutaneous use only. The text warns of serious harm or death if the medication is injected intravenously, and provides the NDC number for the medication. The rest of the text seems to be cut off and unreadable.*
Carton (Principal Panel)
This is a description of a medication called (=lynclally), an extended-release buprenorphine injection. It is intended for subcutaneous use only. The packaging includes a single-dose pre-filled syringe kit, medication guide, prescribing information, and instructions for use. It is important to note that serious harm or death could result if injected intravenously. The medication comes in a 16mg dosage and should only be administered by a healthcare provider and not dispensed directly to the patient.*
Carton (Principal Panel)
This is a medication guide for a drug called buprenorphine extended-release, which is administered through injection for subcutaneous use. The product is contained in a single-dose prefilled syringe kit, with 0.48 mL of buprenorphine in each syringe. There are instructions and warnings on the package indicating that serious harm or death could occur if the drug is injected intravenously. The product is meant to be used weekly, and healthcare providers are instructed not to dispense it to patients. The NDC for the product is 5828422401.*
Carton (Principal Panel)
This is a medication information for a drug called "Buprenorphine" that is used for subcutaneous injection (under the skin injection) on a weekly basis. The package contains a single-use sterile pre-filled syringe with a warning against intravenous usage. The package also contains the medication guide, instructions for use and prescribing information for healthcare providers. The product is not meant to be dispensed to patients directly.*
Carton (Principal Panel)
Carton (Principal Panel)
Ty Clallg is a medication available in a single-dose prefilled syringe kit that contains 96mg of buprenorphine for subcutaneous use. The kit also includes a medication guide, instructions for use, and prescribing information. The warning must not inject intravenously; otherwise, it could lead to serious harm or death. Healthcare providers must administer the medication, and the enclosed medication guide must dispense to each patient. The product is intended for subcutaneous use only.*
Carton (Principal Panel)
This text describes a medication called Ty clallg, which is an extended-release buprenorphine injection used for subcutaneous use. The injection comes in a single-dose prefilled syringe kit, containing 0.36 mL of a 0.35 mg/mL solution per syringe, to be used on a monthly basis. There is a warning that injecting the medication intravenously could result in serious harm or death. It is emphasized that the medication is for subcutaneous use only and the enclosed medication guide should be handed out to each patient. There are also instructions for the use of BRXADI™ syringes, guidance for scheduling, handling and disposal of the medication, and a medication guide, all included in the Prescription Information. This text is intended for healthcare providers and is not to be dispensed to the patient.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
